miR-497 CCNE1在非小细胞肺癌组织中的表达及与预后的关系

doi:10.3969/j.issn.1006-6233.2021.06.016

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1526 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨微小RNA-497(miR-497)、细胞周期蛋白E1(CCNE1)在非小细胞肺癌(NSCLC)组织中的表达特点,分析其与临床病理特征以及患者预后的关系。方法: 选择2016年2月至2017年12月我院收治的102例NSCLC患者,选取手术切除的癌组织(NSCLC组)及癌旁组织(距肿瘤组织边缘≥5cm)(癌旁组)标本,采用实时荧光定量聚合酶链反应(qRT-PCR)检测miR-497、CCNE1表达,Pearson相关性分析miR-497、CCNE1间相关性。分析miR-497、CCNE1与患者临床病理特征关系。术后保持随访,采用Kaplan-Meier法分析不同miR-497、CCNE1表达患者生存率差异,采用Cox比例风险模型分析影响NSCLC患者预后的相关因素。结果: NSCLC组miR-497表达低于癌旁组(P<0.001),CCNE1表达高于癌旁组(P<0.001)。miR-497、CCNE1表达与肿瘤直径、分化程度、TNM分期有关(P<0.001)。Pearson相关性分析结果显示miR-497表达与CCNE1呈负相关(r=-0.539,P<0.001)。Kaplan-Meier生存曲线分析显示miR-497低表达组PFS生存率、OS生存率低于miR-497高表达组(P<0.05),CCNE1高表达组PFS生存率、OS生存率低于CCNE1低表达组(P<0.05)。Cox比例风险回归分析显示TNM分期Ⅲ期、miR-497<0.56、CCNE1≥1.05是NSCLC患者不良预后的危险因素(P<0.01)。结论: NSCLC组织中miR-497表达下调,CCNE1表达上调,miR-497可能通过负向调控CCNE1表达参与NSCLC恶性生物学行为以及不良预后的发生。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	丁灵芝
	罗向军
	陈伟伟
	杨爱珍

关键词 ：微小RNA-497, 细胞周期蛋白E1, 非小细胞肺癌, 病理特征, 预后

Abstract：Objective: To investigate the expressive characteristics of miR-497 and cyclin E1 (CCNE1) in non-small cell lung cancer (NSCLC) tissues, and to analyze the relationship between miR-497, CCNE1 and clinicopathological features and prognosis of patients. Methods: A total of 102 cases of NSCLC admitted to our hospital from February 2016 to December 2017 were selected. Surgical resection of cancerous tissue (NSCLC group) and paracancerous tissue (≥5 cm from the edge of tumor tissue) (paracancerous group) were selected. Real-time quantitative PCR (qRT-PCR) was used to detect the expression of miR-497 and CCNE1, and Pearson correlation was used to analyze the correlation between miR-497 and CCNE1. Postoperative follow-up was maintained, and Kaplan-Meier method was used to analyze the difference in survival rates among patients with different miR-497 and CCNE1 expression, and Cox proportional risk model was used to analyze the related factors affecting the prognosis of NSCLC patients. Results: The expression of miR-497 in NSCLC group was lower than that in paracancerous group (P<0.001), and the expression of CCNE1 was higher than that in paracancerous group (P<0.001). The expression of miR-497 and CCNE1 was correlated with tumor diameter, degree of differentiation and TNM stage (P<0.001). Pearson correlation analysis showed that miR-497 expression was negatively correlated with CCNE1 (r=-0.539,P<0.001). Kaplan-Meier survival curve analysis showed that the PFS and OS survival rates in the group with low miR-497 expression were lower than those in the group with high miR-497 expression (P<0.05), and the PFS and OS survival rates in the group with high CCNE1 expression were lower than those in the group with low CCNE1 expression (P<0.05). Cox proportional hazards regression analysis showed that TNM stage Ⅲ, miR - 497<0.56, CCNE1 acuity 1.05 were risk factors for poor prognosis of NSCLC patients (P<0.01). Conclusion: The expression of miR-497 is down-regulated and the expression of CCNE1 is up-regulated in NSCLC tissues. MiR-497 may be involved in malignant biological behavior and poor prognosis of NSCLC by negatively regulating the expression of CCNE1.

Key words： MicroRNA-497 Cyclin E1 Non-small cell lung cancer Clinicopathological features Prognosis

基金资助:山东省科技发展计划项目,(编号:2017ZRC10070)

引用本文:

丁灵芝, 罗向军, 陈伟伟, 杨爱珍. miR-497 CCNE1在非小细胞肺癌组织中的表达及与预后的关系[J]. 河北医学, 2021, 27(6): 952-957.
DING Lingzhi, LUO Xiangjun, CHEN Weiwei, et al. Expression of MiR-497 and CCNE1 in Non-Small Cell Lung Cancer and Its Relationship with Prognosis. HeBei Med, 2021, 27(6): 952-957.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.06.016 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I6/952

[1] Gao Y,Chen J, Zhang J, et al.Radiofrequency ablation of primary non-small cell lung cancer:a retrospective study on 108 patients[J].BUON,2019,24(4):1610~1618
[2] Jin X,Chen Y,Chen H,et al.Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing[J].Clin Cancer Res,2017,23(17):5311~5319.
[3] 何枫,颜连启,李小磊.miR-429在疾病中的研究进展[J].江苏医药,2017,43(17):1266~1269.
[4] Petersen S,Wilson A J,Hirst J,et al.CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes[J].Gynecol Oncol,2020,157(2):405~410.
[5] Zhang Y,Li X,Zhang J,et al.E6 hijacks KDM5C/Lnc_000231/miR-497-5p/CCNE1 axis to promote cervical cancer progression[J].Cell Mol Med,2020,24(19):11422~11433.
[6] 孙可欣,郑荣寿,曾红梅,等.2014年中国肺癌发病和死亡分析[J].中华肿瘤杂志,2018,40(11):805~811.
[7] Yang G,Xiong G,Cao Z,et al.miR-497 expression, function and clinical application in cancer[J].Oncotarget,2016,7(34):55900~55911.
[8] Feng L,Cheng K,Zang R,et al.miR-497-5p inhibits gastric cancer cell proliferation and growth through targeting PDK3[J].Biosci Rep,2019,39(9):654.
[9] Yang L,Cai Y,Zhang D,et al.miR-195/miR-497 regulate CD274 expression of immune regulatory ligands in triple-negative breast cancer[J].Breast Cancer,2018,21(4):371~381.
[10] 王立,刘永强,王耀华,等.miR-497对前列腺癌细胞生长侵袭及奥沙利铂药物敏感性的影响[J].国际生物医学工程杂志,2020,43(6):440~444,449.
[11] Huang C,Ma R,Yue J,et al.MiR-497 suppresses YAP1 and inhibits tumor growth in non-small cell lung cancer[J].Cell Physiol Biochem,2015,37(1):342~352.
[12] Chae D K, Park J, Cho M,et al.MiR-195 and miR-497 suppress tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-β receptor I ubiquitination[J].Mol Oncol,2019,13(12):2663~2678.
[13] 黄春珍,郑建清,黄碧芬.CCNE1基因表达状态在卵巢癌中的预后价值[J].中外医学研究,2019,17(6):1~2.
[14] Han Z,Zhang Y,Yang Q,et al.miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1)[J].Oncotarget,2015,6(15):13149~13163.